Clinical Trials Logo

Refractory Angina clinical trials

View clinical trials related to Refractory Angina.

Filter by:
  • None
  • Page 1

NCT ID: NCT03455725 Not yet recruiting - Refractory Angina Clinical Trials

CardiAMP CMI Randomized Controlled Pivotal Trial in Patients With Chronic Myocardial Ischemia and Refractory Angina

CardiAMP CMI
Start date: December 2018
Phase: Phase 3
Study type: Interventional

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)

NCT ID: NCT03350737 Recruiting - Clinical trials for Chronic Stable Angina

Coronary Arteriogenetic Heparinized Exercise

CARHEXA
Start date: February 1, 2013
Phase: N/A
Study type: Interventional

This study evaluates the addition of heparin to a 2-week cycle of physical rehabilitation in the treatment of refractory angina. Half of the patients will undergo heparin-primed physical rehabilitation, while the other half will undergo only physical rehabilitation.

NCT ID: NCT03218891 Recruiting - Refractory Angina Clinical Trials

Cardiac Rehabilitation in Patients With Refractory Angina

Start date: January 1, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and feasibility of cardiovascular rehabilitation in Patients with refractory angina, evaluate the effect of cardiovascular rehabilitation in patients with angina Refractory, by maximal oxygen consumption (VO2max) and global myocardial ischemic load by Stress Echocardiography; To evaluate the presence of myocardial injury, caused by physical stress, through ultra-sensitive troponin after sessions of aerobic physical activity, evaluating the behavior during the training period; To evaluate the effect of rehabilitation on the modulation of sympathetic activity and inflammation, muscular blood flow and lipid metabolism; To evaluate of the effect of rehabilitation on ventricular function through Stress echocardiography; Detection of ischemic episodes and arrhythmias identified during the Rehabilitation sessions through external cardiac monitoring (telemetry); Evaluate the quality of life assessment through the SF-36 questionnaire, Canadian Cardiovascular Society, the number of symptomatic episodes of ischemia, daily sublingual nitrate intake.

NCT ID: NCT01966042 Completed - Refractory Angina Clinical Trials

Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina

ReACT
Start date: July 2005
Phase: Phase 2
Study type: Interventional

Therapeutic neovascularization is an innovative strategy for cardiac tissue recovery due to chronic, intense ischemia. Thus stem cell therapy has become a promising procedure for the large number of patients with refractory angina due to coronary disease, despite of the use of multiple anti-angina medications, remain severely symptomatic with disabling angina. Stem cell therapy using autologous cells from the patient's bone marrow, has been shown to be safe and associated with improved myocardial perfusion, reducing the symptoms of advanced coronary artery disease and increasing the functional capacity of patients whose therapeutic armamentarium available today has been exhausted. The study hypothesis was that the infusion of autologous mononuclear cells derived from the patient's bone marrow and delivered via intramyocardial injection in patients with refractory angina and normal or slightly depressed ventricular function, promote improvement in the anginal symptoms and myocardial perfusion by the inducing neoangiogenesis.

NCT ID: NCT01796912 Completed - Refractory Angina Clinical Trials

Lipoprotein Apheresis in Refractory Angina Study

Start date: February 2013
Phase: N/A
Study type: Interventional

Angina which is refractory to conventional medical therapy and revascularisation is challenging to manage. Lipoprotein(a) or Lp(a) is a genetically determined form of LDL-cholesterol, elevation of which is an independent risk factor and predictor of adverse cardiovascular events. Lp(a) is felt to increase cardiovascular risk via its prothrombotic effect and by enhancing intimal lipoprotein deposition. Lipoprotein apheresis is the most effective treatment for raised Lp(a). Lipid lowering agents such as statins have little to no effect on Lp(a) levels. The goal of this study is to determine the impact of apheresis on clinical parameters and symptoms of patients with refractory angina and raised Lp(a). The investigators will conduct a prospective, randomised controlled crossover study of 20 patients with refractory angina and raised Lp(a), randomised to undergoing lipoprotein apheresis weekly for three months or sham apheresis weekly for three months with assessment of myocardial perfusion, carotid atherosclerosis, endothelial vascular function, thrombogenesis, exercise capacity, angina symptoms and quality of life at the beginning and end of treatment. Patients will then crossover to the opposite study arm with the protocol repeated. The hypothesis is that the above parameters will be improved by lipoprotein apheresis in patients with raised Lp(a) and Refractory Angina. Investigators will also test for the genotypic presence of apolipoprotein(a) gene (LPA) locus variants (rs10455872 and rs3798220) which are thought to be associated with an increased level of Lp(a) and an increased risk of coronary disease.

NCT ID: NCT01566175 Recruiting - Refractory Angina Clinical Trials

Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization

Reducer
Start date: August 30, 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to implant the Reducer in patients with the symptoms of refractory angina, that suffer from refractory angina who demonstrate reversible ischemia.

NCT ID: NCT01205893 Completed - Refractory Angina Clinical Trials

Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA

COSIRA
Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the Reducer is safe and effective in treating the symptoms of refractory angina in patients that suffer from refractory angina who demonstrate reversible ischemia.

NCT ID: NCT00820586 Suspended - Refractory Angina Clinical Trials

Intramyocardial Delivery of Autologous Bone Marrow

Start date: May 2007
Phase: Phase 2
Study type: Interventional

A randomized study to assess the safety, feasibility and effectiveness of direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells in patients with refractory angina pectoris.

NCT ID: NCT00694642 Completed - Clinical trials for Coronary Artery Disease

Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis

PROGENITOR
Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether transendocardial injections of autologous endothelial progenitor cells CD 133 is safe and feasible in patients with refractory angina.